Hyaluronidase (human recombinant)
- Generic Name
- Hyaluronidase (human recombinant)
- Brand Names
- Darzalex Faspro, Herceptin Hylecta, Hylenex, Hyqvia 5 G / 50 Ml Kit, Phesgo, Rituxan Hycela, Vyvgart Hytrulo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 757971-58-7
- Unique Ingredient Identifier
- 743QUY4VD8
- Background
A purified preparation of the enzyme recombinant human hyaluronidase. Hyaluronidase (human recombinant) (INN Vorhyaluronidase alfa) is produced by genetically engineered Chinese Hamster Ovary (CHO) cells containing a DNA plasmid encoding for a soluble fragment of human hyaluronidase (PH20). Hyaluronidase is an enzyme used to improve the absorption and disper...
- Indication
Hyaluronidase is indicated for subcutaneous fluid administration for hydration, and increasing resorption of radiopaque agents in subcutaneous urography. Hyaluronidase is also indicated by multiple routes to increase the dispersion of other injectable drugs.
- Associated Conditions
- Drug Extravasation, Generalized Myasthenia Gravis, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Primary Immune Deficiency Disorders (PIDD), Primary Immunodeficiency, Secondary humoral immunodeficiency, Stage I Breast Cancer
- Associated Therapies
- Parenteral rehydration therapy, Improving resorption of radiopaque agents, To increase percutaneous drug absorption therapy
dMAbs for Prevention of COVID-19
- Conditions
- Interventions
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Pablo Tebas
- Target Recruit Count
- 61
- Registration Number
- NCT05293249
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
The Use of a Recombinant DNA-based Hyaluronidase to Dissolve Fixed Amounts of Hyaluronic Acid Dermal Fillers
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Steve Yoelin M.D. Medical Associates, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02654522
Effects of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques
- First Posted Date
- 2013-11-19
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- Tissa Hata, MD
- Target Recruit Count
- 7
- Registration Number
- NCT01987609
- Locations
- 🇺🇸
UCSD Division of Dermatology, San Diego, California, United States
Descriptive Study of Cardiac Output During Rehydration With Recombinant Human Hyaluronidase in Pediatrics
- First Posted Date
- 2010-06-08
- Last Posted Date
- 2018-02-01
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 17
- Registration Number
- NCT01139294
- Locations
- 🇺🇸
Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States
Subcutaneous Rehydration Compared to Intravenous Rehydration
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 148
- Registration Number
- NCT00773175
- Locations
- 🇺🇸
Children's Memorial Hospital, Chicago, Illinois, United States
🇺🇸Rainbow Children's and Babies Hospital, Cleveland, Ohio, United States
🇺🇸Children's Healthcare of Atlanta, Atlanta, Georgia, United States
Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)
- First Posted Date
- 2008-04-11
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 15
- Registration Number
- NCT00656370
- Locations
- 🇺🇸
Jasper Clinic, Kalamazoo, Michigan, United States
INFUSE Morphine Study
- First Posted Date
- 2008-01-14
- Last Posted Date
- 2008-01-14
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 13
- Registration Number
- NCT00593281
- Locations
- 🇺🇸
UCSD Thornton Hospital, San Diego, California, United States
🇺🇸San Diego Hospice and Palliative Care, San Diego, California, United States
A Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recombinant Human Hyaluronidase
- Conditions
- First Posted Date
- 2007-02-15
- Last Posted Date
- 2011-10-17
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 15
- Registration Number
- NCT00435604
A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects
- Conditions
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2006-04-06
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT00311519
- Locations
- 🇺🇸
West Coast Clinical Trials, Long Beach, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.